Second Sight Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St rises on cooler inflation data, big bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Second Sight Medical (EYES) Reports In-Line Q3 EPS
November 14, 2019 4:12 PM ESTSecond Sight Medical (NASDAQ: EYES) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $472 thousand versus the consensus estimate of $940 thousand.
Recent Corporate Highlights:
Reached agreement with the U.S. Food and Drug Administration (FDA) regarding the primary efficacy endpoint to be used in the Orion® Visual Cortical Prosthesis System (Orion) pivotal trial;Presented additional positive data from the Companys Early Feasibility Study of Orion at three scientific conferences in October: the American Academy of Ophthalmology... More